ArticleDiagnostics (Basel, Switzerland)2021
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.Clinical and molecular hepatology · 2024Guideline
- Fruit and vegetable intake and the risk of non-alcoholic fatty liver disease: a meta-analysis of observational studies.Frontiers in nutrition · 2024Pooled it
- Steatotic liver disease subtypes and risk of hospitalization for sepsis: a nationwide cohort study.Annals of medicine · 2026Article
- Article
- Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study.Clinical and molecular hepatology · 2026Article
- Alcohol-driven phenotypic transition in MASLD and risk of liver-related events.JHEP reports : innovation in hepatology · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study.Cancers · 2026Article
- Circulating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study.Current issues in molecular biology · 2026Article
- Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study.Diabetes, obesity & metabolism · 2026Article
- Association between metabolic dysfunction-associated steatotic liver disease and breast cancer risk in Korean women: a nationwide population-based cohort study.Breast cancer research : BCR · 2026Article
- Surveying the features of screening strategies for non-alcoholic fatty liver disease: A scoping review.Journal of education and health promotion · 2026Review
- Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study.PloS one · 2026Article
- Article
- Fatty Liver Index Dynamics as a Predictor of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus and Non-Cirrhotic Livers.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Risk of Hepatocellular Carcinoma in Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2025Article
- Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study.Cardiovascular diabetology · 2025Article
- Risk of pancreatic cancer according to glycemic status in nonalcoholic fatty liver disease: a nationwide cohort study.Scientific reports · 2025Article
- Risk of hepatocellular carcinoma according to body mass index and waist circumference in nonalcoholic fatty liver disease.World journal of gastrointestinal oncology · 2025Article
- Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study.Cardiovascular diabetology · 2025Article
- Synergistic impact of serum uric acid and ferritin on MAFLD risk: A comprehensive cohort analysis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is increasing worldwide, highlighting the importance of early and accurate detection and the appropriate management of NAFLD. However, ultrasonography (US) is not included in many mass screening programs, and people have limited access to it. The aim of this study is to validate the fatty liver index (FLI) and investigate the optimal cutoff value for predicting NAFLD in an asymptomatic population. We conducted a retrospective cohort study in Korea. All subjects who underwent health checkup exams, including abdominal US, controlled attenuation parameter (CAP) and blood testing, were enrolled. Analyses of the area under the receiver operating characteristic curve (AUROC) were used to evaluate the diagnostic accuracy and to calculate the optimal FLI cutoff for US-NAFLD. Among the 4009 subjects (mean age 54.9 years, 83.5% male), the prevalence of US-diagnosed NAFLD and CAP-defined hepatic steatosis was 61.4% and 55.4%. The previously used cutoff of FLI = 60 showed poor performance in predicting US-diagnosed NAFLD, with an AUROC of 0.63 (0.62-0.64), and CAP-defined NAFLD, with an AUROC 0.63 (0.62-0.64). The optimal FLI cutoff values to discriminate fatty liver detected by US were 29 for the entire population, with an AUROC of 0.82 (0.81-0.84). The sex-specific values were 31 for males and 18 for females (sensitivity 72.8% and 73.4%; specificity 74.2% and 85.0%, respectively). The FLI cutoff for US-diagnosed NAFLD can be set as 29 for the entire Korean population. Considering the sex dimorphism in NAFLD, different cutoff values are suggested to predict US-diagnosed NAFLD. These results may be helpful in the accurate non-invasive diagnosis of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.